China’s HUYA Biotech, Solvay Of U.S. To Partner In Drug Development
This article was originally published in PharmAsia News
Executive Summary
China's HUYA Bioscience International has signed a deal with U.S.-based Solvay Pharmaceuticals to share HUYA's portfolio of compounds. HUYA has several compounds for targeting cardiovascular diseases and a partnership with Solvay is seen as one way to speed development and get the drugs to market. Many of the compounds already are in advanced stages of development in China. The Chinese biotech counts two headquarters, one in Shanghai and the other in San Diego. (Click here for more